Recently rebranded SV Health Investors said this week it closed its 6th flagship fund at $400 million. The new SV VI fund will follow suit with previous funds and be multi-sector focused, the group said. The fund will look to invest in early-stage opportunities in biotechnology, early-stage and revenue-stage opportunities in medical devices and growth […]
SV Health Investors
SV Life Sciences rebrands to SV Health Investors
Investment group SV Life Sciences said today it is rebranding to SV Health Investors. The Boston-based company said the new moniker will “better reflect the firm’s longstanding strategy and multi-sector focus.” The investment group said it targets early-stage opportunities in biotechnology, early-stage and revenue stage medical device opportunities and growth equity investments in later-stage businesses in healthcare […]